Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press54210.17650/2313-805X-2023-10-2-70-77REVIEWОБЗОРНАЯ СТАТЬЯProgrammed death ligand 1 (PD-L1) expression in gastric cancer: literature reviewЭкспрессия лиганда рецептора программируемой клеточной гибели 1 (PD-L1) при раке желудка: обзор литературыhttps://orcid.org/0000-0002-6482-1110SotnikovaT. N.СотниковаТ. Н.
Russian Federation

11 Yauzskaya St., Moscow 109240

109240 Москва, ул. Яузская, 11

https://orcid.org/0000-0001-7848-6707DanilovaN. V.ДаниловаН. В.
Russian Federation

Bld. 53, 1 Leninskie Gory, Moscow 119234

119234 Москва, Ленинские горы, 1, стр. 53

https://orcid.org/0000-0001-5074-3513MalkovP. G.МальковП. Г.
Russian Federation

Bld. 53, 1 Leninskie Gory, Moscow 119234

119234 Москва, Ленинские горы, 1, стр. 53

https://orcid.org/0000-0001-7458-991XPolushkinaT. V.ПолушкинаТ. В.
Russian Federation

Tatiana V. Polushkina.

11 Yauzskaya St., Moscow 109240; Bld. 53, 1 Leninskie Gory, Moscow 119234

Полушкина Татьяна Валерьевна.

109240 Москва, ул. Яузская, 11; 119234 Москва, Ленинские горы, 1, стр. 53

peperonya1173@yandex.ruI.V. Davydovsky City Clinical Hospital of the Moscow Healthcare DepartmentГБУЗ «Городская клиническая больница им. И.В. Давыдовского Департамента здравоохранения г. Москвы»Medical Scientific and Educational, Lomonosov Moscow State UniversityМедицинский научно-образовательный центр ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»1505202310270772401202310072023Copyright ©; 2023, Sotnikova T.N., Danilova N.V., Malkov P.G., Polushkina T.V.Copyright ©; 2023, Сотникова Т.Н., Данилова Н.В., Мальков П.Г., Полушкина Т.В.2023Sotnikova T.N., Danilova N.V., Malkov P.G., Polushkina T.V.Сотникова Т.Н., Данилова Н.В., Мальков П.Г., Полушкина Т.В.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/542

Gastric cancer is one of the most common oncological diseases at the present time, so research in this area is very significant and relevant. Immunological checkpoint inhibitors have previously demonstrated  their effectiveness and safety in various solid tumors, however, with regard to stomach cancer, to date, ambiguous results have been presented. Tumor cells express programmed death ligand 1 (PD-L1), which binds to its programmed death receptor 1 (PD-1). Immune defense plays a key role in the initiation and progression of the disease. Understanding the regulatory mechanism of PD-L1 in gastric cancer can lead to significant progress in immunotherapy, as well as contribute to the adequate selection of patients treated with checkpoint inhibitors. In the review, we conducted an in-depth study of PD-L1 expression and regulatory immunosuppressive mechanisms in gastric cancer and methods for assessing PD-L1 status, and also studied the results of current clinical trials in which inhibitors of immunological control points were considered in combination with and without chemotherapy for this oncopathology.

Рак желудка в настоящее время является одним из самых распространенных онкологических заболеваний, что обусловливает значимость и актуальность исследований в этой области. ингибиторы иммунологических контрольных точек ранее продемонстрировали свою эффективность и безопасность при различных солидных опухолях, однако, что касается рака желудка, на сегодняшний день представлены неоднозначные результаты. клетки опухоли экспрессируют лиганд запрограммированной  смерти 1 (PD-L1), который связывается с рецептором запрограммированной смерти 1 (PD-1). иммунная защита играет ключевую роль в инициации и прогрессировании заболевания. понимание регуляторного механизма PD-L1 при раке желудка может привести к существенному прогрессу в иммунотерапии, а также способствовать адекватному отбору пациентов для лечения ингибиторами иммунологических контрольных точек. в обзоре мы провели углубленное исследование экспрессии PD-L1 и регуляторных иммуносупрессивных механизмов при раке желудка, методов оценки PD-L1-статуса, а также изучили результаты текущих клинических испытаний, в которых были рассмотрены ингибиторы иммунологических контрольных точек в комбинации с химиотерапией и без нее при данной онкологической патологии.

gastric cancerimmune cellsligand of programmed cell deathtumorprogrammed death ligand 1receptorssignaling pathwaysрак желудкаиммунные клеткилиганд программируемой клеточной гибели 1опухольрецепторысигнальные путиBray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J Clin 2018;68(6): 394–424. DOI: 10.3322/caac.21492The state of oncological care to the population of Russia in 2018. Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, 2019. 236 p. (In Russ.).Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.Malignant neoplasms in Russia in 2018 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, 2019. 250 p.Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М. : МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11(11):3887–95. DOI: 10.1002/j.1460-2075.1992.tb05481.xAgata Y., Kawasaki A., Nishimura H. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8(5):765–72. DOI: 10.1093/intimm/8.5.765Nishimura H., Nose M., Hiai H. et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11(2): 141–51. DOI: 10.1016/S1074-7613(00)80089-8Freeman B.G.J., Long A.J., Iwai Y. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1028–34. DOI: 10.1084/jem.192.7.1027Iwai Y., Ishida M., Tanaka Y. T. Okazaki et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293–7. DOI: 10.1073/pnas.192461099Taube J.M., Anders R.A., Young G.D. et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4(127):127ra37. DOI: 10.1126/scitranslmed.3003689Tivol E.A., Borriello F., Schweitzer A.N. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3(5):541–7. DOI: 10.1016/1074-7613(95)90125-6Weber J., Thompson J.A., Hamid O. et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;5(17):5591–8. DOI: 10.1158/1078-0432.CCR-09-1024Wolchok J.D., Neyns B., Linette G. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11(2):155–64. DOI: 10.1016/S1470-2045(09)70334-1O’Day S.J., Maio M., Chiarion-Sileni V. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;21(8):1712–7. DOI: 10.1093/annonc/mdq013Hodi F.S., O’Day S.J., McDermott D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711–23. DOI: 10.1056/NEJMoa1003466Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54. DOI: 10.1056/NEJMoa1200690Fuchs C.S., Doi T., Jang R.W. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4(5):e180013. DOI: 10.1001/jamaoncol.2018.0013Ott P.A., Bang Y.-J., Piha-Paul S.P. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 2019;37(4):318–27. DOI: 10.1200/JCO.2018.78.2276Böger C., Behrens H.M., Mathiak M. et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016;7(17):24269–83. DOI: 10.18632/oncotarget.8169Frank G.A., Kuznetsova O.A., Zavalishina L.E. et al. PD-L1 status in breast cancer. Arkh Patol 2019;81(2):3–9. DOI: 10.17116/patol2019810213Garon E.B., Rizvi N.A., Hui R. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018–28. DOI: 10.1056/NEJMoa1501824Dolled-Filhart M., Locke D., Murphy T. et al. Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch Pathol Lab Med 2016;140(11):1259–66. DOI: 10.5858/arpa.2015-0544-OADolled-Filhart M., Roach C., Toland G. et al. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med 2016;140(11):1243–9. DOI: 10.5858/arpa.2015-0542-OAMuro K., Chung H.C., Shankaran V. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17(6):717–26. DOI: 10.1016/S1470-2045(16)00175-3Kulangara K., Zhang N., Corigliano E. et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 2019;143(3):330–7. DOI: 10.5858/arpa.2018-0043-OAFuchs C.S., Doi T., Jang R.W. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4(5):1–8. DOI: 10.1001/jamaoncol.2018.0013Bang Y.J., Kang Y.-K., Catenacci D.V. et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer 2019;22(4):828–37. DOI: 10.1007/s10120-018-00909-5Shitara K., Özgüroğlu M., Bang Y.-J. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastrooesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392( 10142): 123–33. DOI: 10.1016/S0140-6736(18)31257-1Tabernero K.S.J., Van Cutsem E., Bang Y. et al. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase 3 KEYNOTE-062 study. Ann Oncol 2019;30(Suppl. 4):iv152. DOI: 10.1093/annonc/mdz183O’Malley D.P., Yang Y., Boisot S. et al. Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. Mod Pathol 2019;32(7):929–42. DOI: 10.1038/s41379-019-0210-3Yamashita K., Iwatsuki M., Harada K. et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohisto-chemical staining in patients with advanced gastric cancer. Gastric Cancer 2020;23(1):95–104. DOI: 10.1007/s10120-019-00999-9Kang Y.K., Boku N., Satoh T. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10111):2461–71. DOI: 10.1016/S0140-6736(17)31827-5Janjigian Y.Y., Bendell J., Calvo E. et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 2018;36(28):2836–44. DOI: 10.1200/JCO.2017.76.6212Ma J., Li J., Qian M. et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N). Diagn Pathol 2018;13(1):1–10. DOI: 10.1186/s13000-018-0766-0Park Y., Koh J., Na H.Y. et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. 2020 Cancer Res Treat 2020;52(3):661–70. DOI: 10.4143/crt.2019.718Zhang M., Dong Y., Liu H. et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep 2016;6:37933. DOI: 10.1038/srep37933Chang H., Jung W.Y., Kang Y. et al. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. Oncotarget 2016;7(49):80426–34. DOI: 10.18632/oncotarget.12603Harada K., Dong X., Estrella J.S. et al. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer 2018;21(1):31–40. DOI: 10.1007/s10120-017-0760-3Li Y., Wang J., Ke X.Y. Research update on PD-1/PD-L1 pathway in hematological diseases. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011;19(6):1523–7. (In Chinese).